INSIGHTS ON ENTERPRISE SOLUTIONS

• Cell Based Potency Assays: De-Risk Your Path With An Experienced CDMO

  Thorough characterization is key to unlocking the potential of antibody-based therapeutics. Leveraging a CDMO's extensive capabilities and expertise can allow you to navigate the biopharmaceutical development landscape.

• De-Risk Nucleic Acid Therapeutics Through Strategic Outsourcing

  Bringing a nucleic acid therapy to market requires specialized formulation and development knowledge. Innovators need rigorous analytical and formulation strategies to achieve stability and quality.

• Where Sourcing Meets Science: Smarter Collaboration, Better Outcomes

  See how collaboration-driven raw material control reduces variability, improves cell culture performance, and delivers measurable cost and productivity gains in biotherapeutic manufacturing.

• Improving CD Media Titers With Nu-Tek Peptones

  Adding 0.2% soy peptone to chemically defined media increases CHO IgG production by 30–60%. This animal-free supplementation enhances titers while maintaining high process control.

• Yeast Extracts: Improving Expression

  4/17/2026

  Yeast extract improves E. coli protein production by over 50%, boosts desired protein attributes 4X, and offers a secure animal-free nutrient source.

• Life Cycle Assessment Of Extended Use Strategies For Single-Use Assemblies

  4/17/2026

  Examine how extending the use of single‑use assemblies can significantly reduce emissions, resource consumption, and waste in bioprocessing, offering a data‑backed path toward sustainability.

• Maximizing Performance And Quality In Fed-Batch And Perfusion-Based IgG Productions Customer Interview

  4/16/2026

  From lab to production scale: a researcher's firsthand account of what bioreactor scaling and high-density perfusion really demand in practice.

• OneTeam™: Setting A New Standard for Biotech Program Visibility

  4/15/2026

  An on‑demand session showing how integrated governance and real‑time data boost visibility, collaboration, and control in outsourced gene therapy development.